Skip to main content
    J

    Johnson & Johnson (JNJ)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE

    $282.84
    -2.91 (-1.02%)

    Market Cap: $687.89B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Johnson & Johnson (JNJ) P/E Ratio & Valuation History

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Johnson & Johnson (JNJ) trades at 26.6x trailing earnings and 6.9x sales. Its P/E of 26.6x is above its 5-year median of 16.4x. Its forward P/E is 24.1x. The median P/E across 9 similar companies is 19.9x.

    Current Multiples

    Its forward P/E is below its trailing P/E, which implies earnings per share about 10.4% higher over the next year. Its free cash flow yield is 2.9%.

    MultipleValue
    P/E (trailing)26.6x
    Forward P/E24.1x
    Price to sales6.9x
    Price to book8.4x
    EV/EBITDA27.3x
    Price to FCF34.1x
    EV/FCF35.5x
    PEG3.2
    FCF yield2.9%
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/E is 55.6% above 17.1x, its P/S is 43.8% above 4.8x and its P/B is 44.8% above 5.8x.

    MultipleCurrent5-year median10-year median
    P/E26.6x16.4x17.1x
    P/S6.9x5.3x4.8x
    P/B8.4x5.7x5.8x
    Medians of month-end values through Oct 2026: 60 months (5-year) and 120 months (10-year).

    Valuation History

    Over the 10 year ends shown, its P/E ranged from 14.5x in 2024 to 19.6x in 2020.

    Year endPriceP/EP/SP/B
    2025$206.9519.2x5.3x6.2x
    2024$144.6214.5x3.9x4.9x
    2023$156.7415.0x4.7x5.5x
    2022$176.6517.4x5.8x6.1x
    2021$171.0717.5x5.7x6.2x
    2020$157.3819.6x5.0x6.6x
    2019$145.8716.8x4.7x6.5x
    2018$129.0515.8x4.3x5.9x
    2017$139.7219.1x4.9x6.2x
    2016$115.2117.2x4.4x4.5x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewFairly valued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About JNJ

    What is JNJ's forward P/E ratio?

    Johnson & Johnson has a forward P/E ratio of 24.1x.

    Is JNJ stock overvalued?

    GNG's valuation label for JNJ is Fairly valued. Its P/E of 26.6x compares with a median of 19.9x across 9 similar companies.

    What is JNJ's price to sales ratio?

    Johnson & Johnson has a price to sales ratio of 6.9x.

    What is Johnson & Johnson's average P/E ratio over 5 years?

    Johnson & Johnson's median P/E over the last 5 years is 16.4x, from 60 month-end values through Oct 2026.

    What is JNJ's PEG ratio?

    Johnson & Johnson has a PEG ratio of 3.2.